BioCardia Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
31.5%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.71next fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly Net Loss Quarterly-2.3M
Cash and Cash Equivalents Quarterly951K
Active Clinical Sites for CardiAMP HF II Quarterly4.0
Watch Items
- Japan PMDA Shonin Approval Submission for CardiAMP Cell TherapyTrigger: Submission target of Q4 2026Action: Monitor official press releases and regulatory filings for confirmation of submission to Japan's PMDA.
- Nasdaq Listing Compliance (Minimum Stockholders' Equity Requirement)Trigger: Nasdaq staff extension deadline of October 7, 2026Action: Verify if stockholders' equity meets or exceeds the $2.5 million requirement under Nasdaq Listing Rule 5550(b)(1).
- CardiAMP HF II Trial Enrollment ProgressTrigger: Ongoing patient screening and randomization across active clinical sitesAction: Track clinical trial updates and quarterly reports for enrollment milestones and expansion of participating centers.
Research as of 20 Jun 2026